Renal Cell Carcinoma (RCC) Classification – ccRCC, pRCC, and chRCC using New miRNA Biomarker Pane
Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit
Renal cell carcinoma (RCC) consists of an array of morphologically and genetically distinct tumors, the most prevalent of which are clear cell renal cell carcinoma (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC). Accurate distinction between the RCC subtypes poses a challenge for pathologists, as they share a wide range of common features and has overlapping immunohistochemical profiles. Subtypes also have different survival outcomes and responses to therapy. Although surgical resection remains the gold standard treatment for RCC, long-term complications, morbidity and mortality of RCC are difficult to accurately predict. Also, the current approaches to chemotherapy and radiotherapy have only limited efficacy on RCC. Therefore, accurate classification of RCC is critical for clinical decision making. Accumulating evidence has reported microRNAs (miRNAs) as promising biomarkers for early cancer detection, accurate prognosis, as well as molecular targets for cancer treatment. Aberrant expression of miRNAs has been reported to be associated with progression of renal cancer. Evaluation of miRNA profiles in RCC holds promise for improving understanding of pathogenesis and therapeutic outcome.
Super Sensitive Nucleic Acid (SSNA) miRNA probes:
BioGenex has developed proprietary Super Sensitive Nucleic Acid (SSNA) miRNA probes that enhance signals from intrinsically low populated miRNAs. The SSNA oligos are synthesized using specially designed bases to give super high melting temperatures. The high melting temperatures enable stringent washes at elevated temperatures to remove non-specific binding. BioGenex miRNA probes are dual-end labeled on 3’ and 5’ with five FAM molecules that amplify the signal, giving intense stains. The high-density fluorophore-labeled SSNA probes combined with the BioGenex Super Sensitive ™ Detection System aid in studying the lowly expressed miRNA populations and miRNA expression profiles to assess the physiological function of miRNA.
The miRNA expression profiles are used to assess the cancer type or conditions for the below types:
- Cancer of unknown primary
- Undifferentiated and poorly differentiated tumors
- Classification of cancer subtypes
- Grading and staging of cancer
BioGenex is pleased to launch four Super Sensitive Nucleic Acid microRNA in situ hybridization (SSNA miRNA ISH) probes and automated systems for classification of RCC subtypes. Molecular differentiation using the miRNA probes have demonstrated promising results in subclassifying the most common RCC subtypes including renal oncocytomas.
miRNA ISH was performed on 98 formalin-fixed, paraffin-embedded (FFPE) RCC tissues consisting of 37 ccRCC, 28 pRCC, 20 chRCC and 13 oncocytoma cases. miRNA ISH using BioGenex RCC probes demonstrated significant upregulation of miR-126 and miR-222 in ccRCC than pRCC tumor; while miR-222 was non-significantly expressed among the two RCC subtypes. Significant nuclear expression (upregulation) was also reported with miR-200b and miR200C in chRCC compared with oncocytoma cases; while miR-222 was non-significantly expressed. By utilizing the BioGenex product line of miRNA ISH probes and automated Xmatrx® staining, clinical diagnosis time and reliability are significantly improved to better serve patients.
Please click on above links to download Biomarker Panel and Application Note for Renal Cell Carcinoma Classification
BioGenex also has an extensive catalog of over 240 unique miRNA probes